2 citations
,
October 2021 in “Asian Journal of Andrology” This meta-analysis reported that the use of 5α-reductase inhibitors significantly increased the risk of postfinasteride syndrome-like adverse effects in men treated for benign prostatic hyperplasia or androgenetic alopecia.
1 citations
,
September 2025 in “Viruses” This study of HCPS survivors in Chile found that 61.9% reported incomplete recovery at 3-6 months post-symptom onset, with ECMO users experiencing more motor dysfunction and palpitations, highlighting the need for multidisciplinary care to address persistent symptoms.
1 citations
,
August 2025 in “The Egyptian Journal of Internal Medicine” This paper reviews obesity diagnosis and screening methods, emphasizing BMI's practicality in low- and middle-income countries, but provides no new clinical results.
1 citations
,
April 2025 in “Journal of Clinical Medicine” This review reports that alopecia areata negatively affects sexual functioning, highlighting the need for further research due to limitations in current study sizes and populations.
1 citations
,
March 2022 in “IntechOpen eBooks” This chapter discusses various aspects of collagen, proposing "extended collagen carential disease" as a new concept tied to nutritional deficiencies, notably Vitamin C's role in maintaining collagen health.
August 2026 in “Journal of Clinical Medicine” In this study, researchers found that the management of alopecia areata in Poland is inadequate, despite following international guidelines, due to limited access to advanced treatments and insufficient use of severity assessments and psychosocial support.
July 2026 in “IntechOpen eBooks” This research highlights the crucial roles of B vitamins in metabolism, neurological processes, and DNA functions, and describes emerging therapies that enhance vitamin absorption and therapeutic potential.
May 2026 in “Case Reports in Dermatology” This case report detailed a 31-year-old kidney transplant recipient who experienced significant hair loss linked to tacrolimus-based immunosuppression, which improved after switching to cyclosporine A, emphasizing the importance of awareness and management of hair-related side effects in transplant patients.
March 2026 in “Annals of Medicine” This study highlights the importance of developing standardized diagnostic tools, outcome measures, and evidence-based interventions to improve care and long-term outcomes for children and adolescents affected by long COVID-19.
March 2026 in “The American Journal of Managed Care” The authors concluded that FDA-approved JAK inhibitors, shown to be safe and effective in phase 3 trials, are promising treatment options for severe alopecia areata.
This review reported that "Social Botox," encompassing both BTX cosmetic use and societal beauty pressures, significantly influences adolescent self-image, driven by social media and cultural standards, with mixed psychological outcomes, potentially enhancing confidence or exacerbating body dissatisfaction across various cultures.
December 2024 in “Journal of Clinical Medicine” This review explores the hormonal factors linking polycystic ovary syndrome and psychiatric disorders, such as eating disorders, emphasizing a bidirectional relationship that necessitates a multidisciplinary treatment approach; it reports no new clinical results.
March 2024 in “Antioxidants” This study examines the effects of excessive or prolonged exposure to blue light on retinal function and highlights its potential health implications, noting that both photoreceptor and intrinsically photosensitive retinal ganglion cells (ipRGCs) are particularly sensitive to blue wavelengths.
February 2024 in “Endocrinology and Disorders” This article compiles evidence on prescribing estrogen for hormonal imbalance in women, emphasizing it should be personalized and carefully managed by healthcare providers based on individual cases.
January 2024 in “Journal der Deutschen Dermatologischen Gesellschaft” This research paper reviews the mechanisms and management of non-biologic immunosuppressive drugs used in dermatology, highlighting their safety profiles and handling during pregnancy, breastfeeding, and vaccination, but does not report specific results on these aspects.
August 2023 in “Medicina-lithuania” This review discusses the degenerative effects of anabolic-androgenic steroids on the nervous system and reports no new experimental results, aiming to increase public awareness of their health risks.
4 citations
,
January 2025 in “International Journal of Molecular Sciences” This study found that progesterone and its metabolite, allopregnanolone, provided anti-anxiety and anti-depressive effects in female mice, potentially independent of nuclear progestin receptors but requiring 5α-reduction and estradiol's influence on brain-derived neurotrophic factor.
3 citations
,
June 2023 in “Medicina” This study provides a detailed overview of 1,295 clinical trials related to alcohol dependence registered on ClinicalTrials.gov, highlighting that 59.15% of these trials have been completed, primarily as interventional studies, with most located in North America.
July 2021 in “Journal of dermatology research and therapy” In this study, researchers observed an increased incidence of pattern hair loss and telogen effluvium among COVID-19 patients, potentially linked to psychological stress, systemic inflammation, and oxidative stress, with reduced anagenic expression of proteoglycans suggested as a mediating mechanism.
151 citations
,
May 2021 in “Frontiers in Medicine” This systematic review observed that a significant number of COVID-19 patients report long-term symptoms, including neurologic complaints and chronic fatigue, highlighting the presence of "post-COVID syndrome.
September 2022 in “Women's healthcare” This review discusses various aspects of polycystic ovary syndrome, including its prevalence, diagnosis, and treatment options, and reports no new empirical results.
27 citations
,
January 2017 in “Journal of clinical and diagnostic research” This case report details a 23-year-old woman who was poisoned with thallium by a colleague and treated with activated charcoal and Prussian blue.
January 2017 in “Indian journal of sexually transmitted diseases and AIDS” Finasteride, a hair loss drug, can cause sexual side effects like erectile dysfunction in 2.1%-3.8% of users, but these usually go away with time or if the drug is stopped. Despite this, its impact on sexual function is minimal for most men.
11 citations
,
January 2018 in “International Journal of Trichology” This commentary reviews the post-Finasteride syndrome and argues that while the condition's validity is debated, comprehensive guidelines are needed to address related risks and treatment options; it reports no new clinical results.
2 citations
,
December 2024 in “Iraqi Journal of Laser” This study used enhanced Raman spectroscopy to successfully detect ultra-low levels of free testosterone in women with PCOS, suggesting a potential low-cost method for early diagnosis.
2 citations
,
September 2019 in “South Asian research journal of pharmaceutical sciences” This article reviews the risks of metal exposure from cosmetic products and emphasizes the need for stricter regulation and consumer awareness, without presenting new data or results.
7 citations
,
January 2019 in “The Aging Male” This article discusses post-finasteride syndrome as a distinct syndrome related to prolonged use of 5α-steroid reductase inhibitors, noting persistent side effects even after discontinuation and no new research results are reported.
2 citations
,
June 2024 in “Sociological research and innovation” This study highlighted the complex stigma, misinformation, and coping mechanisms among unmarried women with PCOS in Pakistan, emphasizing the role of family support and accurate information in managing emotional well-being.
1 citations
,
November 2023 This study examined the prevalence and management of PCOD, finding that it primarily affects unmarried women aged 18-25, causing symptoms like irregular periods and infertility, with many opting for medication and lifestyle changes despite mixed beliefs about their effectiveness.
1 citations
,
December 2020 in “Dermatology Archives” This study found that pediatric patients with severe alopecia areata showed significant improvement with systemic corticosteroids but typically experienced relapse within 4-5 months, also seeing an increase in weight percentiles.